Drugs Affecting Blood and Blood Formation Practice Questions

Q: Which oral anticoagulant directly inhibits thrombin?

Dabigatran. **Explanation:** **Correct Option: A. Dabigatran** Dabigatran etexilate is a prodrug that is converted into its active form, which acts as a **Direct Thrombin Inhibitor (DTI)**. Unlike indirect inhibitors (like Heparin), it binds directly to both free and clot-bound thrombin (Factor IIa), preventing the conversion of fibrinogen to fibrin. It is currently the only orally administered DTI approved for clinical use. **Analysis of Incorrect Options:** * **B & C (Dicumarol and Warfarin):** These are **Vitamin K Antagonists (VKAs)**. They act indirectly by inhibiting the enzyme Vitamin K Epoxide Reductase (VKOR), thereby preventing the γ-carboxylation of Vitamin K-dependent clotting factors (II, VII, IX, and X). * **D (Rivaroxaban):** This is a Direct Factor **Xa** inhibitor (along with Apixaban and Edoxaban). A helpful mnemonic is that these drugs have "**xa**" in their name (Riva-**xa**-ban). **High-Yield Clinical Pearls for NEET-PG:** * **Antidote:** The specific reversal agent for Dabigatran is **Idarucizumab** (a monoclonal antibody fragment). * **Monitoring:** Unlike Warfarin, Dabigatran does not require routine INR monitoring. However, if needed, **aPTT** or Ecarin Clotting Time (ECT) can be used to assess its effect. * **Elimination:** It is primarily excreted by the **kidneys** (80%); therefore, it is contraindicated in severe renal failure. * **Clinical Use:** Primarily used for stroke prevention in non-valvular atrial fibrillation and treatment of DVT/PE.

Q: All of the following are true about sargramustin except?

It is a G-CSF analog. ### Explanation **Concept:** The primary distinction to understand here is between **G-CSF** (Granulocyte Colony-Stimulating Factor) and **GM-CSF** (Granulocyte-Macrophage Colony-Stimulating Factor). **Why Option A is the correct answer (The "Except"):** **Sargramostim** is a recombinant **GM-CSF** analog, not a G-CSF analog [1]. It stimulates the proliferation and differentiation of a broader range of progenitor cells, including neutrophils, monocytes/macrophages, and eosinophils [2]. In contrast, drugs like **Filgrastim** and **Pegfilgrastim** are G-CSF analogs, which act more selectively on the neutrophil lineage. **Analysis of other options:** * **Option B (Used in neutropenia):** This is a true statement. Sargramostim is clinically indicated to accelerate myeloid recovery following intensive chemotherapy, bone marrow transplantation, or in cases of drug-induced neutropenia [1], [3]. * **Option C (Bone pain):** This is a true statement and a common side effect. Rapid expansion of the bone marrow in response to colony-stimulating factors leads to medullary pressure, manifesting as bone pain (often in the sternum or pelvis). * **Option D (Flu-like symptoms):** This is a true statement. GM-CSF (Sargramostim) is generally more toxic than G-CSF [2]. It can cause a "first-dose reaction" and systemic symptoms like fever, myalgia, arthralgia, and lethargy, mimicking a flu-like syndrome. **NEET-PG High-Yield Pearls:** * **Filgrastim:** G-CSF (Selective for Neutrophils). * **Sargramostim:** GM-CSF (Broad acting: Neutrophils + Macrophages). * **Oprelvekin (IL-11):** Used for Thrombocytopenia (stimulates megakaryocytes). * **Romiplostim/Eltrombopag:** Thrombopoietin receptor agonists used in ITP. * **Side Effect Distinction:** Sargramostim is more likely to cause **Capillary Leak Syndrome** (edema, pleural/pericardial effusions) compared to Filgrastim.

Q: What is the recommended route of administration for low molecular weight heparin (LMWH) for thrombosis prophylaxis in a patient who has recently undergone surgery?

Subcutaneous. ### Explanation **Correct Option: A. Subcutaneous** Low Molecular Weight Heparins (LMWHs), such as Enoxaparin, Dalteparin, and Tinzaparin, are the drugs of choice for perioperative thromboprophylaxis. The **subcutaneous (SC) route** is preferred because LMWHs have high bioavailability (~90%) and a long half-life when administered this way. This allows for predictable pharmacokinetics and once- or twice-daily dosing without the need for routine laboratory monitoring (like aPTT). **Incorrect Options:** * **B. Intravenous (IV):** While Unfractionated Heparin (UFH) is often given as an IV bolus or infusion for immediate anticoagulation (e.g., in PE or MI), LMWH is rarely given IV except in specific protocols like ST-elevation myocardial infarction (STEMI). * **C. Inhalational:** This is not a standard or approved route for heparin delivery due to poor absorption and lack of clinical efficacy. * **D. Intramuscular (IM):** Anticoagulants are **strictly contraindicated** via the IM route because they can cause large, painful, and dangerous **hematomas** at the injection site. **High-Yield Clinical Pearls for NEET-PG:** * **Mechanism:** LMWH acts primarily by inhibiting **Factor Xa** more than Factor IIa (Thrombin), with a ratio of approximately 3:1. * **Monitoring:** Routine monitoring is not required. However, in patients with renal failure, pregnancy, or obesity, **Anti-Xa levels** should be monitored. * **Elimination:** LMWHs are primarily excreted by the **kidneys**; therefore, they are contraindicated or require dose adjustment in patients with renal insufficiency (CrCl <30 ml/min). * **Antidote:** Protamine sulfate only partially neutralizes LMWH (approx. 60%), unlike its complete neutralization of UFH.

Q: Dicumarol, a drug that impairs the utilization of vitamin K by the liver, would decrease the plasma concentration of which of the following procoagulants?

Prothrombin. **Explanation:** **Mechanism of Action:** Dicumarol is a coumarin derivative (similar to Warfarin) that acts as a competitive inhibitor of the enzyme **Vitamin K Epoxide Reductase (VKOR)**. This enzyme is essential for recycling oxidized Vitamin K back to its reduced form (hydroquinone). Reduced Vitamin K is a mandatory cofactor for the **gamma-carboxylation** of glutamate residues on certain clotting factors. Without this post-translational modification, these factors cannot bind calcium or phospholipid surfaces, rendering them biologically inactive. **Why Prothrombin (Factor II) is Correct:** The Vitamin K-dependent clotting factors are **Factors II (Prothrombin), VII, IX, and X**, as well as proteins C and S. Dicumarol specifically impairs the synthesis of these functional factors. Therefore, it directly decreases the plasma concentration of functional **Prothrombin**. **Why Other Options are Incorrect:** * **B. Fibrinogen (Factor I):** Synthesized in the liver but its production is not dependent on Vitamin K. * **C. Antihemophilic factor (Factor VIII):** A cofactor in the intrinsic pathway; it is not Vitamin K-dependent. * **D. Ac-globulin (Factor V):** A cofactor in the common pathway; its synthesis does not require Vitamin K. **NEET-PG High-Yield Pearls:** * **Mnemonic for Vitamin K factors:** "2, 7, 9, and 10" (often remembered as the year **1972**). * **Shortest Half-life:** Factor VII (first to be depleted; monitored by PT/INR). * **Longest Half-life:** Factor II (Prothrombin). * **Antidote for Coumarin toxicity:** Vitamin K1 (Phytonadione) for gradual reversal; Fresh Frozen Plasma (FFP) or Prothrombin Complex Concentrate (PCC) for immediate reversal. * **Teratogenicity:** Coumarins can cause "Fetal Warfarin Syndrome" (chondrodysplasia punctata), unlike Heparin which does not cross the placenta.

Q: All are true about warfarin except:

Protamine sulfate reverses its action. **Explanation:** Warfarin is an oral anticoagulant that acts as a **Vitamin K epoxide reductase (VKOR)** inhibitor. It interferes with the gamma-carboxylation of Vitamin K-dependent clotting factors **II, VII, IX, and X**, as well as proteins C and S. **Why Option B is the correct "Except" answer:** **Protamine sulfate** is the specific antidote used to reverse the effects of **Heparin**, not Warfarin. Protamine is a strongly basic protein that neutralizes acidic heparin molecules. To reverse Warfarin, the treatment of choice is **Vitamin K** (slow onset) or **Prothrombin Complex Concentrate (PCC)/Fresh Frozen Plasma (FFP)** for immediate reversal in cases of life-threatening bleeding. **Analysis of other options:** * **Option A:** Warfarin inhibits the synthesis of functional factor IX (along with II, VII, and X). * **Option C:** Warfarin therapy is monitored using the **Prothrombin Time (PT)**, which is standardized globally as the **International Normalized Ratio (INR)**. * **Option D:** For most clinical indications (like Atrial Fibrillation or DVT), the therapeutic target INR is **2.0–3.0**. For mechanical prosthetic heart valves, a higher range (2.5–3.5) may be required. **High-Yield Clinical Pearls for NEET-PG:** * **Warfarin-induced Skin Necrosis:** Occurs due to a rapid decline in Protein C (short half-life), leading to a transient hypercoagulable state. This is why "Heparin bridging" is necessary. * **Teratogenicity:** Warfarin is contraindicated in pregnancy (Category X) as it causes **Fetal Warfarin Syndrome** (stippled epiphyses, nasal hypoplasia). * **Metabolism:** It is metabolized by **CYP2C9**; enzyme inhibitors (e.g., Amiodarone) increase bleeding risk, while inducers (e.g., Rifampin) decrease its efficacy.

Q: What is the effect of parenteral administration of streptokinase?

May cause bleeding reversible by aminocaproic acid.. **Explanation:** Streptokinase is a first-generation fibrinolytic agent derived from Beta-hemolytic Streptococci. It acts by forming a non-covalent 1:1 complex with **plasminogen**, which then undergoes a conformational change to become an active complex that converts free plasminogen into **plasmin**. Plasmin subsequently degrades fibrin clots. **Why Option D is Correct:** The primary adverse effect of all thrombolytics is systemic bleeding due to the depletion of circulating fibrinogen (systemic lytic state). **Aminocaproic acid** (and Tranexamic acid) acts as a specific antidote by competitively inhibiting plasminogen activation and plasmin activity, thereby reversing the bleeding caused by streptokinase. **Analysis of Incorrect Options:** * **Option A:** Streptokinase does not increase the *formation* of plasminogen; it *activates* existing plasminogen into plasmin. * **Option B:** In the management of ST-elevation myocardial infarction (STEMI), large trials (like GISSI-2 and ISIS-3) showed that streptokinase is **equally effective** as t-PA (Alteplase) in terms of overall mortality reduction, although t-PA has a slight edge in early vessel patency. * **Option C:** Thrombocytopenia is a classic side effect of **Heparin** (HIT), not streptokinase. The main non-bleeding side effect of streptokinase is **hypersensitivity/anaphylaxis** due to its bacterial origin. **NEET-PG High-Yield Pearls:** * **Mechanism:** It is a non-enzymatic activator (unlike t-PA/Urokinase which are enzymes). * **Antigenicity:** Because it is antigenic, it should not be repeated within 6–12 months of prior use due to the risk of neutralization by antibodies or anaphylaxis. * **Specificity:** It is **non-fibrin specific**, meaning it acts on both clot-bound and circulating plasminogen (increasing bleeding risk compared to Tenecteplase).

Q: A patient with Renal cell carcinoma is on treatment with Erythropoetin. Erythropoetin use may be associated with all of the following, except:

Decreased reticulocytes. ### Explanation **Correct Option: A (Decreased reticulocytes)** **Mechanism and Reasoning:** Erythropoietin (EPO) is a glycoprotein hormone produced primarily by the peritubular interstitial cells of the kidney [1]. It acts on the bone marrow to stimulate the proliferation and differentiation of erythroid progenitor cells (CFU-E) [1]. The earliest measurable response to EPO therapy is an **increase in the reticulocyte count** (immature red blood cells), which typically occurs within 7–10 days [2]. Therefore, saying EPO causes *decreased* reticulocytes is physiologically incorrect, making it the right answer for an "except" question. **Analysis of Incorrect Options:** * **B & C (Increased hematocrit and hemoglobin):** These are the primary therapeutic goals of EPO [2]. As reticulocytes mature into erythrocytes, the total red cell mass increases, leading to a rise in hemoglobin levels and hematocrit [2]. * **D (Eliminates need for transfusion):** In patients with chronic anemia (e.g., due to Chronic Kidney Disease or chemotherapy), EPO is used specifically to maintain hemoglobin at a target level (usually 10–12 g/dL), thereby reducing or eliminating the requirement for frequent blood transfusions and avoiding iron overload [2]. **High-Yield Clinical Pearls for NEET-PG:** * **Most Common Side Effect:** Hypertension (due to rapid increase in peripheral resistance and blood viscosity). * **Black Box Warning:** Increased risk of thromboembolic events (Stroke, MI) if Hemoglobin is targeted >11-12 g/dL [1]. * **Iron Stores:** EPO therapy can lead to "functional iron deficiency" because iron utilization outpaces supply; thus, iron supplementation is often required concurrently [2]. * **Indications:** Anemia of CKD, Anemia in HIV (Zidovudine-induced), and Anemia in cancer patients on chemotherapy [2].

Q: All of the following statements are true regarding warfarin toxicity (skin necrosis) except?

Most common sites are buttocks and abdomen.. **Explanation:** Warfarin-induced skin necrosis (WISN) is a rare but severe complication occurring in approximately 0.01% to 0.1% of patients treated with vitamin K antagonists. **Why Option B is the correct answer (The False Statement):** While the buttocks and abdomen are common sites, the **most common sites** for warfarin necrosis are areas with **high subcutaneous fat content**, specifically the **breasts** (in females), followed by the thighs and buttocks. The statement in Option B is considered the "except" because it overlooks the breast as the primary site of predilection. **Analysis of Other Options:** * **Option A:** True. Necrosis typically occurs **3 to 10 days after initiation** of therapy, often due to a large loading dose. * **Option C:** True. Warfarin inhibits Vitamin K-dependent factors (II, VII, IX, X) and anticoagulant proteins (C and S). **Protein C has a shorter half-life** (6 hours) compared to clotting factors. This creates a transient "prothrombotic window" where natural anticoagulants are depleted while procoagulant factors are still active, leading to microvascular thrombosis. * **Option D:** True. Starting **Low Molecular Weight Heparin (LMWH)** as a "bridge" provides immediate anticoagulation, preventing the thrombotic complications during the initial drop in Protein C levels. **Clinical Pearls for NEET-PG:** * **Risk Factor:** Underlying **Protein C deficiency** is the most significant risk factor. * **Clinical Presentation:** Sudden onset of painful, erythematous, or purpuric lesions that rapidly progress to **hemorrhagic bullae and eschar**. * **Management:** Immediate discontinuation of Warfarin, administration of **Vitamin K**, and starting **Heparin** or Protein C concentrates.

Q: A patient with acute kidney injury (creatinine > 4) has been undergoing dialysis in the ICU for 15 days and has developed deep vein thrombosis (DVT) due to immobilization. What is the most appropriate anticoagulant to administer?

Argatroban. ### Explanation The management of anticoagulation in patients with severe renal impairment (AKI or ESRD) requires careful selection based on the route of drug elimination. **Why Argatroban is the Correct Choice:** Argatroban is a parenteral Direct Thrombin Inhibitor (DTI) [1]. Its primary clinical advantage in this scenario is its **hepatic metabolism and biliary excretion**. Unlike many other anticoagulants, its clearance is independent of renal function. In a patient with a creatinine > 4 mg/dL undergoing dialysis, Argatroban can be administered without the risk of accumulation or toxicity, making it the safest choice among the options provided. **Analysis of Incorrect Options:** * **Desirudin & Lepirudin:** Both are recombinant hirudins (DTIs) that are **predominantly cleared by the kidneys**. In patients with renal failure, these drugs have a significantly prolonged half-life, leading to a high risk of life-threatening hemorrhage. (Note: Lepirudin has largely been withdrawn from many markets due to this risk and immunogenicity). * **Aspirin:** Aspirin is an antiplatelet agent, not an anticoagulant [1]. It is ineffective for the treatment of established Deep Vein Thrombosis (DVT). **NEET-PG High-Yield Pearls:** * **Drug of Choice for HIT:** Argatroban is also the preferred anticoagulant for patients with Heparin-Induced Thrombocytopenia (HIT) who have renal failure [1]. * **Monitoring:** Argatroban is monitored using **aPTT** (target 1.5–3 times the baseline). * **Renal vs. Hepatic:** Remember the mnemonic: **A**rgatroban = **A**liver (Liver/Hepatic clearance); **L**epirudin = **L**eaving via kidney (Renal clearance). * **LMWH/Fondaparinux:** These are generally contraindicated or require extreme caution/dose reduction when CrCl < 30 ml/min [1].

Q: Low molecular weight dextran is contraindicated in which of the following conditions?

Thrombocytopenia. **Explanation:** **Low Molecular Weight Dextran (Dextran-40)** is a plasma volume expander used to improve microcirculation. However, it is strictly contraindicated in **Thrombocytopenia** and other bleeding disorders. **Why Thrombocytopenia is the correct answer:** Dextran-40 exerts a potent anti-platelet effect. It coats the surface of platelets and vascular endothelium, reducing platelet adhesiveness and interfering with the function of **von Willebrand Factor (vWF)** and Factor VIII. In a patient with a low platelet count (thrombocytopenia), this further impairment of primary hemostasis significantly increases the risk of life-threatening hemorrhage. Additionally, it can induce "Dextran-induced nephrosis," which is exacerbated in dehydrated states. **Analysis of Incorrect Options:** * **Fetal Distress Syndrome:** Dextran is not contraindicated here; in fact, volume expanders may be used in maternal resuscitation to improve placental perfusion. * **Cerebrovascular Accident (CVA):** Dextran-40 is often used in ischemic stroke to decrease blood viscosity and improve cerebral blood flow (rheological effect), though its routine use is now debated. * **Electrical Burns:** Fluid resuscitation is the mainstay of burn management. While crystalloids are preferred (Parkland formula), dextrans are not specifically contraindicated unless there is associated acute kidney injury or active bleeding. **High-Yield Clinical Pearls for NEET-PG:** * **Mechanism:** Reduces blood viscosity and prevents "sludging" of RBCs. * **Adverse Effects:** Anaphylaxis (most common serious reaction), prolonged bleeding time, and acute renal failure. * **Interference:** Dextran can interfere with blood grouping and cross-matching; therefore, blood samples should be drawn *before* administration. * **Contraindications:** Severe CHF, Renal failure, Thrombocytopenia, and Hypofibrinogenemia.

Question 1

Which oral anticoagulant directly inhibits thrombin?

Accepted Answer

Dabigatran

Answer

Dicumarol

Answer

Warfarin

Answer

Rivaroxaban

Question 2

All of the following are true about sargramustin except?

Accepted Answer

It is a G-CSF analog

Answer

It is used in cases of neutropenia

Answer

Chronic usage can lead to bone pain

Answer

It can also lead to flu-like symptoms

Question 3

What is the recommended route of administration for low molecular weight heparin (LMWH) for thrombosis prophylaxis in a patient who has recently undergone surgery?

Accepted Answer

Subcutaneous

Answer

Intravenous

Answer

Inhalational

Answer

Intramuscular

Question 4

Dicumarol, a drug that impairs the utilization of vitamin K by the liver, would decrease the plasma concentration of which of the following procoagulants?

Accepted Answer

Prothrombin

Answer

Fibrinogen

Answer

Antihemophilic factor (factor VIII)

Answer

Ac-globulin (factor V)

Question 5

All are true about warfarin except:

Accepted Answer

Protamine sulfate reverses its action

Answer

Acts through inhibition of coagulation factor IX

Answer

Monitoring is done through INR

Answer

Target INR with warfarin is generally 2-3

Question 6

What is the effect of parenteral administration of streptokinase?

Accepted Answer

May cause bleeding reversible by aminocaproic acid.

Answer

Increases the formation of plasminogen.

Answer

Is less effective following a myocardial infarct than t-PA.

Answer

Causes a high incidence of thrombocytopenia.

Question 7

A patient with Renal cell carcinoma is on treatment with Erythropoetin. Erythropoetin use may be associated with all of the following, except:

Accepted Answer

Decreased reticulocytes

Answer

Increased hematocrit

Answer

Increased hemoglobin

Answer

Eliminates need for transfusion

Question 8

All of the following statements are true regarding warfarin toxicity (skin necrosis) except?

Accepted Answer

Most common sites are buttocks and abdomen.

Answer

Skin necrosis occurs during initiation of therapy.

Answer

Decreased quantity of protein C.

Answer

Decreased incidence of adverse effects if therapy with LMWH is started.

Question 9

A patient with acute kidney injury (creatinine > 4) has been undergoing dialysis in the ICU for 15 days and has developed deep vein thrombosis (DVT) due to immobilization. What is the most appropriate anticoagulant to administer?

Accepted Answer

Argatroban

Answer

Desirudin

Answer

Lepirudin

Answer

Aspirin

Question 10

Low molecular weight dextran is contraindicated in which of the following conditions?

Accepted Answer

Thrombocytopenia

Answer

Fetal distress syndrome

Answer

Cerebrovascular accident

Answer

Electrical burns

Drugs Affecting Blood and Blood Formation — MCQs

Drugs Affecting Blood and Blood Formation — MCQs

On this page

Practice by Chapter

Want unlimited practice?